Management

Management

by dparker

Grace Terrell MD, MMM

President & CEO

Dr. Grace Terrell is CEO of Envision Genomics, a company helping clinicians diagnose rare disease through the integration of genomic data into clinical care. At Envision Genomics, she is focused on the integration of precision medicine technology into population health frameworks for patients with rare, misdiagnosed, and undiagnosed disorders to improve the triple aim 100-fold. She is a national thought leader in health care innovation and delivery system reform, and a serial entrepreneur in population health outcomes driven through patient care model design, clinical and information integration , and value-based payment models.

In 1995 she and seven other physicians founded Cornerstone Health Care, a multi-specialty medical practice now part of the Wake Forest Baptist Health System. While CEO, Cornerstone grew from 42 physicians and $16 M in annual revenues to 375 providers and $250 M in revenues and won AMGA’s prestigious Acclaim Award, had the best performing MSSP Track 1 ACO in the country, was the first system-wide Patient Centered Medical Home in North Carolina, and was one of the first organizations to make the “move to value” by lowering the cost of care and improving its quality for the sickest, most vulnerable patients in various care models by 13-20%.

In 2013, Dr. Terrell launched CHESS, a population health management company that brought the innovations of the Cornerstone care model redesign process to a wider group of health care systems. She served as CEO of CHESS until it was acquired by LabCorp and Wake Forest Baptist Health in 2016. CHESS currently has greater than 120,000 lives under management in various risk-based contracts.

Dr. Terrell currently serves on the U.S. Department of Health and Human Services’ Physician-Focused Payment Model Technical Advisory Committee, the Board of Directors of the American Medical Group Association, and the Oliver Wyman Health Innovation Center’s Leadership Alliance.

Jill Tapper, MHA, CG (ASCP)CM

Founder | Chief Operating Officer & Vice President of Medical Genomics

Ms. Tapper has over 15 years of experience directing the operations of clinical genetics laboratories and programs.  She has a Master’s degree in Healthcare Administration, a Bachelor’s Degree in Health Science and holds ASCP certification as a Specialist in Cytogenetics. In addition to her administrative leadership experience, she is an accomplished clinical technologist who has multiple peer-reviewed publications in the areas of clinical genetics, cytogenetics, and molecular diagnostics.  Ms. Tapper served as the Administrator of Human & Molecular Genetics Center at the Medical College of Wisconsin (MCW) from 2011-2105.  Her expertise in the financial, business, and management aspects of the clinical laboratory industry, coupled with her technical knowledge were instrumental in the successful development and operationalization of the Clinical Sequencing Laboratory in the HMGC at MCW.  This laboratory was one of the first to offer a fully-interpreted clinical whole genome sequencing test.  Ms. Tapper has worked with Dr. Jacob and the Founder team to create the vision for Envision Genomics.

Elizabeth Worthey, PhD

Founder | Chief Product Development Officer

Dr. Worthey is a faculty investigator and the director of informatics at the Hudson Alpha Institute for Biotechnology. Her research focuses on the clinical and translational use of genomic data, including the development and implementation of methods and tools for analysis of sequencing data in order to impact the lives of people with a wide spectrum of diseases. Her work is focused on bringing solutions to hospitals and clinics interested in Genomic Medicine. Dr. Worthey received her PhD from Imperial College, London, and did her postdoctoral training at the University of Washington. Prior to joining the Hudson Alpha Institute she was an assistant professor and director of genomic informatics at the Medical College of Wisconsin and she also worked as a research at Rosetta Inpharmatics a wholly owned subsidiary of Merck. Her undergraduate studies were undertaken at Glasgow University, Oxford University, and the University of Birmingham in Immunology, Computer Science, and Quantitative Genetics.

David Bick, MD

Founder | Chief Medical Officer

David Bick has more than 20 years of clinical experience as a board certified clinical geneticist and experience translating molecular testing from the research laboratory to the clinical diagnostic laboratory as a board certified clinical molecular geneticist.

David Bick received his medical degree from George Washington University School of Medicine in 1981 and completed his residency in Pediatrics at Yale-New Haven Hospital in New Haven, CT. At the Yale University School of Medicine, Bick completed a fellowship in Human Genetics and Pediatrics in 1986, followed by a postdoctoral research fellowship in Human Genetics in 1987. Bick is board-certified in pediatrics, clinical genetics, and clinical molecular genetics. He joined the Medical College of Wisconsin (MCW) in 2002 where he was the Director of the Clinical Sequencing Laboratory and Chief of the Division of Genetics in the Department of Pediatrics at MCW, and Director of the Advanced Genomics Laboratory and Medical Director of the Genetics Clinic at Children’s Hospital of Wisconsin. In 2015 he became the Chief Medical Officer, faculty investigator, the Medical Director of the Smith Family Clinic for Genomic Medicine, and a laboratory director in the Clinical Services Laboratory at the HudsonAlpha Institute for Biotechnology.